Baird lowered the firm’s price target on Mind Medicine (MNMD) to $16 from $27 and keeps an Outperform rating on the shares. The firm noted both Phase 3 trials of MM120 for GAD are enrolling witht he first results expected in the first half of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNMD:
- Buy Recommendation for Mind Medicine: Promising Phase 3 Trials and Undervalued Market Potential
- Mind Medicine’s Promising Future: Buy Rating Backed by Strong Phase 3 Prospects and Financial Position
- MindMed Advances Clinical Trials and Strengthens Financial Position
- Psychedelic: MindMed reports Q4 earnings results
- Mind Medicine reports Q4 EPS (41c), consensus (28c)